Researchers evaluated the antiviral efficacy of harmol in treating herpes simplex virus-induced keratitis and enhancing acyclovir effects. Herpes simplex keratitis (HSK) can lead to blindness and encephalitis if left untreated. Harmol, a β-carboline alkaloid with antiviral properties, inhibited HSV-1 replication in vitro and in a mouse model. It also showed effectiveness against ACV-resistant strains and combats early viral-induced lesions. Harmol’s safety was confirmed in mouse corneas, with no adverse effects observed. The study suggests that harmol could be a potential treatment for HSK and other HSV infections, offering new hope in combating drug resistance.
Source link
Evaluating the efficacy of harmol in treating herpes simplex virus-induced keratitis
